Navigation Links
Warning on Avastin Updated

A new label change has been proposed by the FDA for the anti-angiogenic colorectal-cancer drug Avastin (bevacizumab) to include rare cases of a reversible posterior leukoencephalopathy syndrome in its warning.//

Genentech, which markets Avastin said that the brain-capillary leak syndrome has been reported or confirmed in less than 0.1% of the estimated 60,000 cancer patients treated with Avastin.

The Adverse Reactions and Dosage and Administration sections of the Avastin label have been updated to include the warning about reversible posterior leukoencephalopathy as well as nasal septum perforation.

Genentech reported seven cases of nasal septum perforation reported in post market surveillance.

Reversible posterior leukoencephalopathy syndrome is also associated with fluid retention, hypertension and the cytotoxic effects of the immunosuppressive drugs on the vascular endothelium.

J. Leonard Lichtenfeld, M.D., deputy medical director of the American Cancer Society in Atlanta, said this not the first time that the anti-angiogenic agent has been linked with bleeding problems. He noted, for example, the perforated colon has been reported in Avastin colorectal cancer studies.

Dr. Lichtenfeld said, "This is exactly the reason that post marketing surveillance is so important for all drugs and especially for chemotherapy drugs."

According to him Avastin is "typically is given to patients with advanced disease and aggressive tumors," a patient population that is compromised by disease and thus at higher risk for side-effects.

Genetech letter’s to the clinicians said that reversible posterior leukoencephalopathy usually presents with "headache, seizure, visual disturbance, and altered mental function, and is characterized by reversibility upon control of hypertension or other instigating factors," with onset of symptoms reported to occur within 16 hours to one year of initiation of Avastin treat ment.

Magnetic resonance imaging studies are needed to confirm diagnosis.

Patients who develop symptoms of reversible posterior leukoencephalopathy should discontinue Avastin and initiate hypertension treatment, if necessary.

Genetech also says that symptoms "usually resolve or improve within days, although some patients have experienced ongoing neurologic sequelae." It is still unknown however whether Avastin can safely be reinitiated in patients who developed reversible posterior leukoencephalopathy syndrome.


NLA
'"/>




Related medicine news :

1. Early Warning System For Breast Cancer
2. Warning on radiowave exposure
3. A Seizure Late In Life Could be A Stroke Warning
4. Blood Pressure An Early Warning Sign Of Alzheimer’s Disease
5. Early Warning Signs Of Heart Disease
6. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
7. Warning issued by FDA over "Liqiang 4 Capsules"
8. Warning Signs On Powered Baby Milk
9. People Still Neglect To Use Sunscreen In Spite Of Cancer Warnings
10. Global Outbreak Of Bird Flu Warning By Chinese Scientist
11. Experts Building Bird Flu Warning System
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots ... scientists from around the world, announces the launch of its newly redesigned website. ... portal to research breakthroughs and trending news, vital information on upcoming virtual events ...
(Date:1/19/2017)... ... , ... Cosmetic Town, an online plastic surgery community, begins 2017 with an ... for their readers to get the information they desire. The procedures are now listed ... used on those particular areas. , “We are excited to streamline our listings in ...
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... certified dermatologist by the American Board of Dermatology and fellowship trained Mohs and ... the National Institutes of Health, Dr. Li completed his internship in internal medicine ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... doctor who administered fillers that resulted in severe facial disfiguration. After four frightening ... on by doctors at UCLA Medical Center, who removed the substances in a ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... and privacy panel system. , The Tranquility privacy panel system was designed ... office environment. Tranquility panels help reduce noise and provide the visual privacy required ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor ... market is expected to grow at a CAGR of 27.1% ... 38.7% in the second half of the forecast period. The market ... to 2027. The market is estimated at $1,058 million in 2016, ... ...
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... January 19, 2017 New ... to Address Motor Symptoms and Motor Complications in ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) C ... European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
Breaking Medicine Technology: